Compare AAT & LTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AAT | LTGO |
|---|---|---|
| Founded | 1967 | N/A |
| Country | United States | United States |
| Employees | 208 | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 2010 | 2026 |
| Metric | AAT | LTGO |
|---|---|---|
| Price | $22.77 | $19.49 |
| Analyst Decision | Sell | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $19.50 | N/A |
| AVG Volume (30 Days) | 388.5K | ★ 581.8K |
| Earning Date | 04-28-2026 | N/A |
| Dividend Yield | ★ 6.65% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $436,204,000.00 | N/A |
| Revenue This Year | $4.33 | N/A |
| Revenue Next Year | $0.22 | N/A |
| P/E Ratio | $287.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.72 | $17.22 |
| 52 Week High | $25.97 | $20.50 |
| Indicator | AAT | LTGO |
|---|---|---|
| Relative Strength Index (RSI) | 39.12 | 64.63 |
| Support Level | $18.23 | N/A |
| Resistance Level | $25.76 | N/A |
| Average True Range (ATR) | 0.52 | 1.48 |
| MACD | -0.10 | 0.14 |
| Stochastic Oscillator | 23.43 | 56.10 |
American Assets Trust Inc is a self-administered real estate investment trust based in the United States. The company invests in, operates, and develops retail, office, residential, and mixed-use properties. Properties are predominantly located in South California, Northern California, Oregon, Washington, and Hawaii. American Assets operates through four segments based on property type: retail; office; mixed-use, which consists of retail and hotel components; and multifamily, which includes the company's apartment properties. The retail and office segments collectively contribute the majority of the total revenue.
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.